George A. Scangos, Ph.D.
Chairman
George A. Scangos, Ph.D. assumed the position of Chairman of our Board on December 31, 2005. He has served as a member of Anadys' Board of Directors since October 2003. Since 1996, Dr. Scangos has been President and Chief Executive Officer of Exelixis, Inc. From 1993 to 1996, he served as President of Biotechnology at Bayer Corporation. At Bayer, Dr. Scangos held several positions, including Senior Vice President of Research and Development for Bayer's pharmaceutical division and then President of Bayer Biotechnology.

He serves on the Board of Visitors at the University of California, San Francisco School of Pharmacy, the Board of Overseers at the University of California, Davis Medical School and the Boards of Directors of Entelos, Inc., and Exelixis.

Mark G. Foletta, CPA
Director
Mark G. Foletta joined our Board of Directors in September 2005. Mr. Foletta has served as Senior Vice President, Finance and Chief Financial Officer at Amylin Pharmaceuticals since March 2006. He has previously served as Vice President, Finance and Chief Financial Officer since March 2000. Previously, he served as a Principal of Triton Group Management, Inc. from 1997 to 2000. From 1986 to 1997, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd., the most recent of which was Senior Vice President, Chief Financial Officer and Corporate Secretary. From 1982 to 1986, Mr. Foletta was with Ernst & Young, most recently serving as an Audit Manager. Mr. Foletta earned his B.A. in Business Economics from the University of California, Santa Barbara. Mr. Foletta is a certified public accountant.

Marios Fotiadis
Director
Marios Fotiadis has served as a member of our board of directors since September 2002. In November 2007 he was appointed as General Partner at TVM Capital. Previously, he was Managing Director of life sciences investments at Enterprise Partners Venture Capital in La Jolla, California and a Venture General Partner at Advent International since 2004. Prior to joining Advent, he was with SG Capital Partners since 1999 and oversaw its portfolio in life sciences. Prior to 1999, Mr. Fotiadis was an investment banker focusing on mergers and acquisitions transactions with SG Cowen, an entity related to SG Capital Partners. Mr. Fotiadis holds an M.B.A. from Columbia University and a B.S.B.A. degree cum laude in Business Administration from the Daniels College of Business at the University of Denver.

Steven H. Holtzman
Director
Steven H. Holtzman joined our Board of Directors in August 2004. Mr. Holtzman is a founder and the Chairman and Chief Executive Officer of Infinity Pharmaceuticals, Inc. He previously was the Chief Business Officer of Millennium Pharmaceuticals, Inc., the founder and Executive Vice President of DNX Corporation, the founding Executive Director of the Ohio Edison Program, and an instructor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K. Mr. Holtzman co-founded and from 1995-2000 was the Co-Chair of the Biotechnology Industry Organization (BIO) Bioethics Committee and, from 1996-2001, served as a Member of the National Bioethics Advisory Commission. He is also a Trustee of The Hastings Center for Ethics and the Life Sciences and the Berklee College of Music. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar.

Stelios Papadopoulos, Ph.D.
Director
Stelios Papadopoulos, Ph.D. is a co-founder of Anadys and has served as a member of our board of directors since May 2000. Dr. Papadopoulos' career in biotech spans more than two decades. In August 2006 he resigned as Vice Chairman of Cowen & Co., LLC, where he had been an investment banker focusing on the biotechnology and pharmaceutical sectors since 2000. Dr. Papadopoulos was an investment banker at PaineWebber Incorporated from 1987 to 2000, most recently serving as Chairman of Paine Webber Development Corp, a PaineWebber subsidiary focusing on biotechnology. Prior to joining PaineWebber Incorporated in 1987, he was a Vice President in the Equity Research Department of Drexel Burnham Lambert covering the biotechnology industry and prior to that a biotechnology analyst at Donaldson, Lufkin & Jenrette. Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with New York University Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University. He is co-founder and Chairman of the Board of Exelixis, Inc., co-founder and member of the Board of Cellzome Inc., as well as a member of the Board of Directors of Biogen Idec and BG Medicine, Inc. In the not-for-profit sector, he is co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke University Medical Center.

Douglas E. Williams, Ph.D.
Director
Douglas E. Williams, Ph.D., joined our Board of Directors in August 2004. Dr. Williams currently serves as President and Chief Scientific Officer of ZymoGenetics, Inc. Prior to joining ZymoGenetics, Dr. Williams served as Chief Scientific Officer and Executive Vice President, Research and Development of Seattle Genetics. Previously, he served as Senior Vice President, Washington Site Leader and member of the Executive Committee for Amgen, Inc. following Amgen's acquisition of Immunex Corp., where he served from 1988 to 2002, most recently as Executive Vice President, Chief Technology Officer and a member of Immunex's Board of Directors. Dr. Williams currently serves on the Board of Directors of Array Biopharma and Aerovance, Inc. He is also a member of the Scientific Advisory Board of Symphony Capital in New York. Dr. Williams holds a B.S. magna cum laude in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Division..

Kleanthis G. Xanthopoulos, Ph.D.
Director
Kleanthis G. Xanthopoulos, Ph.D., has served as a member of the Board of Directors since May 2000. On November 20, 2006 he stepped down as President and CEO, and is currently President and Chief Executive Officer of Regulus Therapeutics as of December 2007. Dr. Xanthopoulos was a founder of Anadys Pharmaceuticals and served as President and Chief Executive Officer from May 2000 to November 2006. From 1997 to 2000 he held a variety of positions at Aurora Biosciences Corporation, including Vice President, Genomics & Molecular Biology. Dr. Xanthopoulos was a Section Head of the National Human Genome Research Institute at The National Institutes of Health. He was a Postdoctoral Research Fellow at the Rockefeller University from 1987 to 1990 and an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Sweden from 1991 to 1995. Dr. Xanthopoulos is also a member of the board of directors of Odyssey Thera, Inc. and BIOCOM, Southern California's life science industry association. An Onassis Scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.

Steve Worland, Ph.D.
President, Chief Executive Officer & Director
Steve Worland, Ph.D. was appointed President and Chief Executive Officer and a member of the Board of Directors on August 24, 2007. Dr. Worland joined Anadys as Chief Scientific Officer in 2001. In October 2004 he was promoted to Executive Vice President, Head of Research and Development, in December 2005. Dr. Worland was named Executive Vice President, Pharmaceuticals, and in June 2006 he was promoted to President, Pharmaceuticals. From 1999 to 2001 he was Vice President, Head of Antiviral Research, at Agouron Pharmaceuticals, a Pfizer Company. Dr. Worland was at Agouron from 1988 through the acquisition of Agouron by Warner-Lambert in 1999,where he held various positions and responsibilities that culminated with him assuming global responsibility for anti-infective strategy as Vice President for Warner-Lambert. At Agouron, Warner-Lambert and Pfizer, Dr. Worland led teams responsible for discovery and clinical development in the areas of HIV, HCV and Rhinovirus. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. He received his B.S. in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.